Cargando…
Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials
BACKGROUND: Thanks to the advances in genomics and targeted treatments, more and more prediction models based on biomarkers are being developed to predict potential benefit from treatments in a randomized clinical trial. Despite the methodological framework for the development and validation of pred...
Autores principales: | Ternès, Nils, Rotolo, Federico, Michiels, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441049/ https://www.ncbi.nlm.nih.gov/pubmed/28532387 http://dx.doi.org/10.1186/s12874-017-0354-0 |
Ejemplares similares
-
Identification of biomarker‐by‐treatment interactions in randomized clinical trials with survival outcomes and high‐dimensional spaces
por: Ternès, Nils, et al.
Publicado: (2016) -
Prediction of treatment benefit in high-dimensional cox models via gene signatures in randomized clinical trials
por: Ternès, Nils, et al.
Publicado: (2015) -
Accounting for grouped predictor variables or pathways in high-dimensional penalized Cox regression models
por: Belhechmi, Shaima, et al.
Publicado: (2020) -
Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice
por: Michiels, S., et al.
Publicado: (2016) -
Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis
por: Lueza, Béranger, et al.
Publicado: (2016)